Chemotherapy Combinations With Monoclonal Antibodies in Non-Hodgkin’s Lymphoma

Por Kahl, Brad
Publicado em 2008

Follicular lymphoma: are we ready for a risk-adapted approach?

Por Kahl, Brad S.
Publicado no Hematology Am Soc Hematol Educ Program (2017)

Current and emerging treatment options for mantle cell lymphoma

Por Fakhri, Bita, Kahl, Brad
Publicado no Ther Adv Hematol (2017)

The Role of rituximab for newly diagnosed, refractory or relapsed aggressive B‐cell lymphoma in adult patients

Por Fitzmaurice, Christina, Zinke, Richard, Heraly, Bradley, Kahl, Brad
Publicado no Cochrane Database Syst Rev (2016)

Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis

Por Abouraya, Mahmoud, Sacco, James C, Kahl, Brad S, Trepanier, Lauren A
Publicado em 2011

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

Por Yang, David T, Young, Ken H, Kahl, Brad S, Markovina, Stephanie, Miyamoto, Shigeki
Publicado em 2008

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

Por PETRICH, ADAM, KAHL, BRAD, BAILEY, HOWARD, KIM, KYUNGMANN, TURMAN, NANCY, JUCKETT, MARK
Publicado em 2008

A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma

Por Goy, André, Hernandez-Ilzaliturri, Francisco J., Kahl, Brad, Ford, Peggy, Protomastro, Ewelina, Berger, Mark
Publicado no Leuk Lymphoma (2014)

Use of Tissue Microarray and Automated Quantitative Analysis For Screening and Validation of Potential Biomarkers in Mantle Cell Lymphoma

Por Yang, David T., Quann, Philip J., Petrich, Adam M., Leith, Catherine P., Young, Ken H., Kahl, Brad S.
Publicado em 2011

Microscale functional cytomics for studying hematologic cancers

Por Young, Edmond W. K., Pak, Chorom, Kahl, Brad S., Yang, David T., Callander, Natalie S., Miyamoto, Shigeki, Beebe, David J.
Publicado em 2012

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Por Thapa, Bicky, Caimi, Paolo F., Ardeshna, Kirit M., Solh, Melhem, Carlo-Stella, Carmelo, Kahl, Brad S., Hamadani, Mehdi
Publicado no Blood Adv (2020)

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab

Por Treon, Steven P., Soumerai, Jacob D., Hunter, Zachary R., Patterson, Christopher J., Ioakimidis, Leukothea, Kahl, Brad, Boxer, Michael
Publicado em 2011

Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma

Por Chang, Julie E., Juckett, Mark B., Callander, Natalie S., Kahl, Brad S., Gangnon, Ronald E., Mitchell, Teri L., Longo, Walter L.
Publicado em 2008

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial

Por Advani, Ranjana H., Hong, Fangxin, Horning, Sandra J., Kahl, Brad S., Manola, Judith, Swinnen, Lode J., Habermann, Thomas M., Ganjoo, Kristen
Publicado em 2011

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20 + indolent NHL: Correlation between clinical responses and AUC pharmac...

Por Casulo, Carla, Vose, Julie M., Ho, William Y., Kahl, Brad, Brunvand, Mark, Goy, Andre, Kasamon, Yvette, Cheson, Bruce, Friedberg, Jonathan W.
Publicado no Clin Immunol (2014)

Autologous vs. Reduced Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response or...

Por Tomblyn, Marcie R., Ewell, Marian, Bredeson, Christopher, Kahl, Brad S., Goodman, Stacey A., Horowitz, Mary M., Vose, Julie M., Negrin, Robert S., Laport, Ginna G.
Publicado em 2010

A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

Por Greenwald, Daniel R, Li, Hailun, Luger, Selina M, Go, Ronald S, King, David, Patel, Taral, Gascoyne, Randy D, Kolesar, Jill, Kahl, Brad S, Horning, Sandra
Publicado em 2013

Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Group Study (E2404)

Por Ganjoo, Kristen, Hong, Fangxin, Horning, Sandra J., Gascoyne, Randy D., Natkunam, Yasodha, Swinnen, Lode J., Habermann, Thomas M., Kahl, Brad S., Advani, Ranjana H.
Publicado em 2013

A Phase II Trial of R-CHOP Followed by Radioimmunotherapy for Early Stage (Stages I/II) Diffuse Large B-Cell Non-Hodgkin Lymphoma: ECOG3402

Por Witzig, Thomas E., Hong, Fangxin, Micallef, Ivana N., Gascoyne, Randy D., Dogan, Ahmet, Wagner, Henry, Kahl, Brad S., Advani, Ranjana H., Horning, Sandra J.
Publicado no Br J Haematol (2015)

Fc gamma receptor 3A and 2A polymorphisms do not predict response to rituximab in follicular lymphoma

Por Kenkre, Vaishalee P., Hong, Fangxin, Cerhan, James R., Lewis, Marcia, Sullivan, Leslie, Williams, Michael E., Gascoyne, Randy D., Horning, Sandra J., Kahl, Brad S.
Publicado no Clin Cancer Res (2015)